Lpath Announces New Antibody Program, Altepan™, Targeting Respiratory Disease
Anti-leukotriene antibodies were generated with ImmuneY2™, Lpath's
SAN DIEGO, Nov. 21, 2013
SAN DIEGO, Nov. 21, 2013 /PRNewswire/ -- Lpath, Inc. (Nasdaq: LPTN), the
category leader in lipid-targeted therapeutics, has used its proprietary
discovery technology to generate several monoclonal antibody product
candidates targeting the leukotriene family of bioactive lipids. Leukotrienes
are implicated in numerous inflammatory processes. The lead antibody, which
binds to and neutralizes several different leukotriene isoforms, has shown
positive in vivo results, and testing in animal models of respiratory disease,
including asthma, is now underway.
"The scientific literature on the leukotriene pathway, coupled with our
preliminary in vivo data, suggests that Lpath's approach of specifically
targeting the bioactive lipid rather than the proteins themselves may have
significant benefits over prior drug-discovery efforts in this area," said
Gary Woodnutt, Ph.D., Lpath's senior vice president of research. "If the data
continue to be positive and our preclinical development efforts are
successful, we intend to file an IND sometime in late 2015."
Lpath's CEO, Scott Pancoast notes, "Our ImmuneY2 platform has again provided
Lpath with a new promising program, underscoring the power and value of the
technology. We look forward to updating investors on this and other
advancements in the future."
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is
the category leader in lipidomics-based therapeutics, an emerging field of
medicine that targets bioactive signaling lipids for treating a wide range of
human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability
to generate therapeutic antibodies that bind to and inhibit bioactive lipids
that contribute to disease. The company has developed four drug candidates,
two of which—iSONEP™ for wet AMD and ASONEP™ for cancer—are currently being
investigated in Phase 2 trials. The other candidates are an anti-LPA antibody
that holds promise in neuropathic pain and neurotrauma and an anti-leukotriene
antibody that holds promise in respiratory disease. For more information,
About Forward-Looking Statements
The Company cautions you that the statements included in this press release
that are not a description of historical facts are forward-looking statements.
These include statements regarding: the potential benefits and therapeutic
uses of the monoclonal antibody product candidates the Company developed to
target the leukotriene family of bioactive lipids, the Company's ability to
successfully complete additional preclinical studies, development activities
and clinical trials for these drug candidates; and the Company's ability to
develop additional drug candidates utilizing its proprietary ImmuneY2 drug
discovery process. Actual results may differ materially from those set forth
in this press release due to the risks and uncertainties inherent in the
Company's business. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set
forth in the Company's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and its Quarterly Reports on Form
10-Q filed with the SEC. Such documents may be read free of charge on the
SEC's web site at www.sec.gov.You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to revise or
update this press release to reflect events or circumstances after the date
hereof. This caution is made under the safe harbor provisions of Section 21E
of the Private Securities Litigation Reform Act of 1995.
Scott R. Pancoast
President and CEO
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Robert H. Uhl
SOURCE Lpath, Inc.
Press spacebar to pause and continue. Press esc to stop.